On July 28, the Food and Drug Administration (FDA) approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Read more
Test Your Knowledge
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.